Snap-8 Doses Used in Published Studies: What Researchers Reported

The short answer

People looking for a SNAP-8 injection dosage chart will not find one in the published record summarised here, and none is provided on this page. SNAP-8 (acetyl octapeptide-3, also written acetyl glutamyl heptapeptide-1) is a cosmetic ingredient family member that sits alongside acetyl hexapeptide-8, the peptide sold under the name Argireline. The peer-reviewed studies that can be cited for this ingredient class describe topical concentrations in finished formulations, in vitro exposures in diffusion cells and cell culture, and regulatory safety review of cosmetic use — not milligram doses delivered by needle. A 2025 review of acetyl hexapeptide-8 concentrated specifically on skin permeability and efficacy in topical products rather than on systemic administration (PMID 40565185), and a 2024 review of cosmeceuticals in photoaging likewise discussed peptides as ingredients applied to the skin surface (PMID 39233460).

How SNAP-8 relates to the peptides that have actually been studied

SNAP-8 is an eight-amino-acid analogue modelled on the same N-terminal region of the SNAP-25 protein that inspired the six-amino-acid acetyl hexapeptide-8. Because the two share that design logic, they are frequently discussed together in cosmetic chemistry, but they are chemically distinct molecules, and a finding for one is not automatically a finding for the other. Nearly all of the verifiable primary literature in this area involves the hexapeptide: a 2020 clinical-terminology review examined acetyl hexapeptide-8 in the context of temporary camouflage of scars and wrinkles in dermatology and onco-esthetics (PMID 33151254), and the 2025 permeability review catalogued how formulation determines whether the peptide reaches viable skin layers at all (PMID 40565185). Readers searching for SNAP-8 numbers are therefore usually reading across from a neighbouring molecule, which is one more reason that translating any published figure into a personal amount is not supportable.

What each published study actually administered

Topical application in people

The most frequently cited human work is the 2002 report describing a synthetic hexapeptide with antiwrinkle activity, in which researchers applied a 10% water/oil emulsion of the peptide topically to the periorbital area of healthy female volunteers for 30 days and reported a reduction in wrinkle depth of up to roughly 30% (PMID 18498523). That study measured a cosmetic surface endpoint after a month of twice-daily topical use in a small volunteer group; it did not involve injection, systemic exposure, or a body-weight-based dose. A separate monocentric clinical study delivered bioactive peptides using dissolving hyaluronic acid microneedle patches applied to facial skin and reported improvements in the wrinkle-related parameters the investigators tracked (PMID 31134751). Microneedle patches breach the stratum corneum mechanically, but the study still described a patch-based cosmetic application rather than a syringe-delivered dose.

Laboratory skin-penetration models

Several papers exist precisely because delivering these peptides through skin is difficult. One in vitro study assessed skin penetration of acetyl hexapeptide-8 from a finished cosmetic formulation using excised skin mounted in diffusion cells and reported that the peptide's movement into and across skin was limited (PMID 24754410). A companion line of work compared topical delivery of acetyl hexapeptide-8 from different emulsions and reported that emulsion composition and internal structure influenced how much peptide was delivered (PMID 25497319). A 2018 paper took a chemical approach instead, modifying anti-wrinkle peptides at the molecular level and reporting enhanced skin permeation relative to the unmodified peptides (PMID 29371611). In a related formulation example with a different active, oligomeric hyaluronic acid-modified liposomes were reported to improve skin permeability and anti-ageing activity of ellagic acid (PMID 40715158), illustrating how heavily outcomes in this field depend on the delivery vehicle rather than on a headline ingredient percentage.

Cell culture

Work in isolated cells uses exposure concentrations in culture medium, which are not doses in any clinical sense. One study applied five cosmeceutical peptide mixtures to human skin fibroblasts challenged with hydrogen peroxide and reported protective and anti-aging effects against the induced premature senescence (PMID 33849044). Cultured fibroblasts sit in direct contact with the test article, bypassing the stratum corneum barrier that the penetration studies above showed to be the limiting step (PMID 24754410), so concentrations used in a dish cannot be mapped onto anything applied to or introduced into a living person.

Reviews and safety assessment

A 2025 safety assessment of acetyl hexapeptide-8 amide evaluated the ingredient as used in cosmetics, framing exposure in terms of product category and concentration of use rather than administered dose (PMID 40673537). The 2024 photoaging review placed peptides among other cosmeceutical ingredient classes used on the skin surface (PMID 39233460), and the 2025 permeability review summarised efficacy claims alongside the barrier problem (PMID 40565185).

Summary of what was administered, by study

Why the record describes concentrations rather than injected doses

A percentage in a cream describes how much ingredient is in the jar, not how much reaches living tissue. That distinction is the central theme of the penetration literature: the same peptide behaved differently depending on the emulsion it was carried in (PMID 25497319), and chemical modification changed permeation without changing the peptide's nominal concentration (PMID 29371611). Because these molecules were developed and evaluated as cosmetic ingredients, the regulatory literature frames them the same way, assessing acetyl hexapeptide-8 amide as used in cosmetic products (PMID 40673537). Nothing in this verified set characterises injected SNAP-8 in humans or animals, and no pharmacokinetic profile, clearance value or body-weight-scaled amount appears in it.

Why study doses do not translate into a recommendation

• Different molecule. Most primary data describe acetyl hexapeptide-8, not SNAP-8, and the reviews that cover the ingredient class treat permeability and efficacy as formulation-specific questions (PMID 40565185).
• Different route. A 10% topical emulsion used for 30 days in a volunteer study cannot be converted into any injected quantity (PMID 18498523), because the barrier that governs topical exposure is absent when a needle is used.
• Different model. Diffusion-cell and fibroblast experiments expose tissue directly and are designed to compare formulations or mechanisms, not to establish human exposure levels (PMID 24754410, PMID 33849044).
• Different endpoints. The human studies measured cosmetic surface outcomes such as wrinkle depth and related parameters over short periods (PMID 18498523, PMID 31134751), not systemic safety endpoints.
• Small, short studies. The reported volunteer work ran for weeks in small groups (PMID 18498523), which cannot support statements about long-term or repeated non-topical exposure.

Tolerability and Adverse Events: What Studies Report

The safety literature available here is cosmetic-ingredient safety literature. A 2025 assessment reviewed acetyl hexapeptide-8 amide as used in cosmetics, evaluating it in the context of cosmetic product categories and concentrations of use (PMID 40673537). Reviews of the ingredient class have emphasised that limited penetration constrains both effect and systemic exposure from topical products (PMID 40565185, PMID 24754410). A dermatology review discussed acetyl hexapeptide-8 in the setting of temporary camouflage of scars and wrinkles, again in topical use (PMID 33151254). None of these sources characterised adverse events after injection of SNAP-8, and an absence of reported events in cosmetic use is not evidence of safety by another route.

What remains unstudied in this literature

Across the verified papers there is no human or animal injection study of SNAP-8, no dose-ranging work, no comparison of injected versus topical exposure, and no long-term follow-up. The available primary findings are a short topical volunteer study with a 10% emulsion (PMID 18498523), a microneedle-patch clinical study (PMID 31134751), formulation and permeation experiments (PMID 25497319, PMID 29371611, PMID 40715158), and cell-culture work (PMID 33849044). That is the whole evidentiary base a reader can inspect, and it is why this page describes what was administered instead of offering a schedule. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning a specific substance, product or personal health decision.

References

• A synthetic hexapeptide (Argireline) with antiwrinkle activity (International Journal of Cosmetic Science, 2002)
• In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation (Cutaneous and Ocular Toxicology, 2015)
• Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure (European Journal of Pharmaceutical Sciences, 2015)
• Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification (Scientific Reports, 2018)
• Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study (Journal of Cosmetic Dermatology, 2020)
• Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8 (La Clinica Terapeutica, 2020)
• Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts (Skin Pharmacology and Physiology, 2021)
• Cosmeceuticals in photoaging: A review (Skin Research and Technology, 2024)
• Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy (International Journal of Molecular Sciences, 2025)
• Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics (International Journal of Toxicology, 2025)
• Oligomeric hyaluronic acid-modified liposomes effectively improved skin permeability and anti-ageing activity of ellagic acid (Scientific Reports, 2025)